If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Core Laboratories (CLB) . This company, which is in the Zacks Oil and Gas - Field Services industry, shows potential for another earnings beat. This energy services company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for th ...

Core Laboratories Inc. (CLB) is an oilfield services company, operating in more than 50 countries, providing reservoir management and production enhancement to oil and gas companies. Despite a challenging market, CLB's shares have risen 13.9% year to date (YTD), outperforming the broader oil and energy sector's 8.2% growth. Additionally, CLB has not only surpassed the Field Services sub-industry but has also outperformed competitors like ProFrac Holding Corp. (ACDC) and Tetra Technologies (TTI) . YTD Price ...

OPEC's latest 'World Oil Outlook' paints a bullish picture for oil demand through to 2050, positioning itself as a staunch defender of the idea that oil and gas will remain crucial to global energy. For market participants, this theory offers a compelling long-term buying opportunity. Investors interested in the sector could benefit from having quality stocks Core Laboratories (CLB) , TechnipFMC plc (FTI) and Tullow Oil (TUWOY) . Demand Growth in the Foreseeable Future OPEC firmly believes that the global d ...

The Oils-Energy group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Core Laboratories (CLB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Oils-Energy peers, we might be able to answer that question. Core Laboratories is one of 246 individual stocks in the Oils-Energy sector. Collectively, these companies sit at #16 in the Zacks Sector Rank. The Zacks Sector Rank incl ...

Core Laboratories (CLB) has been beaten down lately with too much selling pressure. While the stock has lost 10.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillato ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Investors interested in Oils-Energy stocks should always be looking to find the best-performing companies in the group. Is Core Laboratories (CLB) one of those stocks right now? By taking a look at the stock's year-todate performance in comparison to its Oils-Energy peers, we might be able to answer that question. Core Laboratories is one of 247 companies in the Oils-Energy group. The Oils-Energy group currently sits at #14 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector gr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ______________ Commission File Number: 001-41695 CORE LABORATORIES INC. (Exact name of registrant as specified in its charter) Delaware 98- ...

Financial Data and Key Metrics Changes - Revenue for Q2 2024 was $130.6 million, a slight increase from $129.6 million in Q1 2024 and $127.9 million in Q2 2023, driven by increased demand in the U.S. and certain international regions [9][22] - Operating income improved sequentially, with operating margins increasing from 12% to 13% [17][22] - Free cash flow for the quarter was $14.3 million, contributing to a total of $16.8 million for the first half of 2024, a significant improvement from $1.2 million in the same period last year [35] Business Line Data and Key Metrics Changes - In the Reservoir Description segment, revenue increased by over 2% compared to Q1 2024, with operating margins at 14% [14][54] - The Production Enhancement segment saw a revenue decline of approximately 2% compared to Q1 2024, but operating margins improved to 10%, up over 260 basis points due to cost control measures [15][40] Market Data and Key Metrics Changes - Demand for laboratory-based reservoir rock and fluid analytical programs continues to improve globally, particularly in certain international regions, despite geopolitical conflicts impacting demand [9][14] - The U.S. frac spread count is trending lower, indicating a soft market for the remainder of the year, although international and offshore diagnostic services are expected to offset declines in U.S. onshore activity [25][52] Company Strategy and Development Direction - The company aims to introduce new product and service offerings in key geographic markets, maintain a lean organization, and focus on deleveraging to strengthen its balance sheet [17][18] - Core Laboratories is committed to maximizing free cash flow and returning excess cash to shareholders while investing in growth opportunities [18][90] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued volatility in crude oil markets due to global economic and geopolitical risks, but projects growth in demand for proprietary services and products [24][52] - The company expects third quarter 2024 revenue to range from $131 million to $137 million, with operating income projected between $16.9 million and $19.1 million [36] Other Important Information - The company reduced its net debt by $15.8 million or 10%, lowering its leverage ratio to 1.66, the lowest in five years [16][23] - G&A expenses for the quarter were $10.3 million, up from $8.3 million in the prior quarter, primarily due to changes in company-owned life insurance investments and new initiatives [30] Q&A Session Summary Question: Emulsion treatment plant and opportunities in the U.S. - Management elaborated on the emulsion treatment plant's role in identifying problematic wells and emphasized the potential for addressing emulsion issues in the U.S. land market [60][65] Question: Insights from international meetings - Management found the meetings with international operators reaffirming and inspiring, indicating a positive outlook for future work and capital investment [67] Question: Impact of natural gas prices on U.S. activity - Management noted that firmer natural gas prices could support increased drilling and completion activity in the U.S., and highlighted the potential benefits of market consolidations for Core Laboratories [72][72] Question: Efficiency in drilling and completion - Management clarified that while drilling activity does not directly impact revenue, the complexity of completions drives demand for Core's services, suggesting that longer and more complex wells are beneficial for the company [73][74]

Core Laboratories Overview - Core Laboratories reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.21 per share, and matching earnings from the previous year [8] - The company posted revenues of $130.58 million for the quarter ended June 2024, which was 1.33% below the Zacks Consensus Estimate, but an increase from $127.88 million year-over-year [2] - Core Laboratories has surpassed consensus EPS estimates two times over the last four quarters [9] Stock Performance - Core Laboratories shares have increased approximately 26.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The stock's immediate price movement will depend on management's commentary during the earnings call and future earnings expectations [10] Future Earnings Expectations - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $136.15 million, and for the current fiscal year, it is $0.94 on revenues of $537.13 million [5] - The estimate revisions trend for Core Laboratories is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [12] Industry Context - The Oil and Gas - Field Services industry, to which Core Laboratories belongs, is currently ranked in the bottom 13% of over 250 Zacks industries, which may impact stock performance [13] - Another company in the same industry, Archrock Inc., is expected to report revenues of $270.59 million, reflecting a 9.3% increase from the previous year [7]